Previous 16‐week‐studies and subsequent clinical trials have shown that the monoclonal anti‐IL‐4Rα antibody can substantially improve the AD symptoms in adults, adolescents and children between 6 and 11 years of age, with acceptable safety.19, 20, 21. This evidence concerns the gene IL4R and Alzheimer disease.